Article Text

Download PDFPDF
Terbinafine used safely in autoimmune hepatitis for treatment of tinea corporis
  1. Jessica Elizabeth Ferguson1 and
  2. Megan Prouty2
  1. 1University of Kansas Medical Center, Kansas City, Kansas, USA
  2. 2Division of Dermatology, The University of Kansas Health System, Kansas City, Kansas, USA
  1. Correspondence to Ms Jessica Elizabeth Ferguson; jferguson{at}


Terbinafine is often considered contraindicated in those with liver disease, as one of the known side effects is hepatotoxicity. We report the first case documenting the safe use of oral terbinafine in a 77-year-old woman with stable autoimmune hepatitis presenting with extensive tinea corporis. Precautions were carried out to minimise the risk of worsening hepatotoxicity, including consultation with the patient’s hepatologist, limiting terbinafine exposure to less than 6 weeks, monitoring of liver function tests, and patient education. The patient’s fungal infection cleared without any signs or symptoms of worsening liver disease. The rash had not recurred 6 months after treatment. When terbinafine must be used in a patient with pre-existing liver disease, we recommend considering a short course of oral terbinafine after consultation with their hepatologist, obtaining baseline liver function tests with consideration of further monitoring during treatment course, and patient education on the signs and symptoms of liver injury.

  • dermatology
  • contraindications and precautions
  • liver disease
  • drugs: infectious diseases

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors JEF was the lead author and reported the information in the manuscript. This author was the one who received patient consent. MP planned the case report and was supplemental in writing the document. This author helped with next step decisions to create and publish the report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.